• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Abstracts from the 3rd International PPRI Conference 2015: Pharmaceutical Pricing and Reimbursement Policies: Challenges Beyond the Financial Crisis.

作者信息

Vogler Sabine, Zimmermann Nina, Ferrario Alessandra, Wirtz Veronika J, Babar Zaheer-Ud-Din

机构信息

WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Health Economics Department, Gesundheit Österreich GmbH (Austrian Public Health Institute), Vienna, 1010, Austria

LSE Health and Department of Social Policy, London School of Economics and Political Science, London, WC2A 2AE, UK

出版信息

J Pharm Policy Pract. 2015 Oct 5;8 Suppl 1(Suppl 1):E1-P29. doi: 10.1186/2052-3211-8-S1-E1.

DOI:10.1186/2052-3211-8-S1-E1
PMID:28256984
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4602344/
Abstract
摘要

相似文献

1
Abstracts from the 3rd International PPRI Conference 2015: Pharmaceutical Pricing and Reimbursement Policies: Challenges Beyond the Financial Crisis.2015年第三届国际药品定价与报销政策会议摘要：金融危机之外的挑战
J Pharm Policy Pract. 2015 Oct 5;8 Suppl 1(Suppl 1):E1-P29. doi: 10.1186/2052-3211-8-S1-E1.
2
Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference.危机中的药品政策？PPRI会议确定的挑战与解决方案
J Pharm Policy Pract. 2016 Mar 15;9:9. doi: 10.1186/s40545-016-0056-8. eCollection 2016.
3
Pharmaceutical policies in European countries in response to the global financial crisis.欧洲国家应对全球金融危机的药品政策。
South Med Rev. 2011 Dec;4(2):69-79. doi: 10.5655/smr.v4i2.1004. Epub 2011 Dec 2.
4
Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference.通过平衡、证据、合作与透明度应对药品可及性挑战：第四届PPRI会议的关键经验教训
J Pharm Policy Pract. 2021 Jan 25;14(1):18. doi: 10.1186/s40545-021-00300-3.
5
Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.中国的药品定价与报销：整体为何小于部分之和。
Health Policy. 2016 May;120(5):519-34. doi: 10.1016/j.healthpol.2016.03.014. Epub 2016 Apr 12.
6
European pharmaceutical pricing and reimbursement conference.欧洲药品定价与报销会议。
Expert Rev Pharmacoecon Outcomes Res. 2009 Feb;9(1):37-9. doi: 10.1586/14737167.9.1.37.
7
Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK.《2010年欧洲药品定价与市场准入展望》——HealthNetwork通信公司第四届年度会议。2010年3月24日至25日，英国伦敦
IDrugs. 2010 May;13(5):317-20.
8
[Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].[卫生技术评估及其对药品定价和报销政策的影响]
Rev Med Chil. 2014 Jan;142 Suppl 1:S33-8. doi: 10.4067/S0034-98872014001300006.
9
Abstracts from the 3rd International PPRI Conference, October 12-13, 2015, Vienna, Austria.2015年10月12日至13日于奥地利维也纳召开的第三届国际PPRI会议摘要。
J Pharm Policy Pract. 2015 Oct 5;8 Suppl 1(Suppl 1):K1-P29. doi: 10.1186/2052-3211-8-S1-E1. eCollection 2015.
10
PRICING, REIMBURSEMENT, AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINAL PRODUCTS IN BULGARIA.保加利亚药品的定价、报销和医疗技术评估。
Int J Technol Assess Health Care. 2017 Jan;33(3):365-370. doi: 10.1017/S0266462317000551. Epub 2017 Aug 23.

引用本文的文献

1
'We need to be part of the solution': lessons from the 2024 PPRI Conference on ensuring access to affordable medicines through innovative policies.“我们需要成为解决方案的一部分”：2024年药品价格监管指数（PPRI）会议关于通过创新政策确保可及负担得起药品的经验教训
J Pharm Policy Pract. 2024 Dec 24;17(Suppl 1):2442002. doi: 10.1080/20523211.2024.2442002. eCollection 2024.
2
An assessment of the implications of distribution remuneration and taxation policies on the final prices of prescription medicines: evidence from 35 countries.分销报酬和税收政策对处方药最终价格的影响评估：来自35个国家的证据
Eur J Health Econ. 2025 Apr;26(3):513-536. doi: 10.1007/s10198-024-01706-x. Epub 2024 Sep 19.
3
The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias.血脂异常管理中获取新兴疗法的障碍及潜在解决方案
J Clin Med. 2024 Jul 16;13(14):4160. doi: 10.3390/jcm13144160.
4
Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally.激励新型抗生素和诊断试剂进入市场的定价、采购和报销政策：全球 10 个国家的经验教训。
Appl Health Econ Health Policy. 2024 Sep;22(5):629-652. doi: 10.1007/s40258-024-00888-y. Epub 2024 Jun 5.
5
Variables affecting new drug prices in South Korea's pricing system.韩国定价体系中影响新药价格的变量。
Front Pharmacol. 2024 May 9;15:1370915. doi: 10.3389/fphar.2024.1370915. eCollection 2024.
6
Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries.20个国家的先进治疗药品定价与报销机制
Front Pharmacol. 2023 Nov 28;14:1199500. doi: 10.3389/fphar.2023.1199500. eCollection 2023.
7
Performance of a pharmaceutical services regionalization strategy policy in Minas Gerais, Brazil: Pre-post analysis from ERAF project.巴西米纳斯吉拉斯州药品服务区域化战略政策的实施：来自ERAF项目的前后分析。
Front Pharmacol. 2022 Sep 2;13:953990. doi: 10.3389/fphar.2022.953990. eCollection 2022.
8
Does external reference pricing deliver what it promises? Evidence on its impact at national level.外部参考定价能否如其承诺的那样发挥作用？国家层面的影响证据。
Eur J Health Econ. 2020 Feb;21(1):129-151. doi: 10.1007/s10198-019-01116-4. Epub 2019 Oct 3.
9
Variations in external reference pricing implementation: does it matter for public policy?外部参考定价实施的差异：这对公共政策有影响吗？
Eur J Health Econ. 2019 Dec;20(9):1375-1397. doi: 10.1007/s10198-019-01100-y. Epub 2019 Aug 23.
10
Policies to improve access to pharmaceutical products in shortage: the experience of Iran food and drug administration.改善短缺药品可及性的政策：伊朗食品药品监督管理局的经验。
Daru. 2019 Jun;27(1):169-177. doi: 10.1007/s40199-019-00259-2. Epub 2019 Mar 23.

本文引用的文献

1
Causes of drug shortages in the legal pharmaceutical framework.合法制药框架下药品短缺的原因。
Regul Toxicol Pharmacol. 2015 Mar;71(2):251-8. doi: 10.1016/j.yrtph.2015.01.005. Epub 2015 Jan 12.
2
Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden.应对新药的不确定性和高昂价格：对比分析比利时、英格兰、荷兰和瑞典的药品评估定价协议使用情况
Soc Sci Med. 2015 Jan;124:39-47. doi: 10.1016/j.socscimed.2014.11.003. Epub 2014 Nov 5.
3
Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems.罕见病很常见，常见病代价高：罕见病对医疗保健系统构成挑战。
Eur J Health Econ. 2015 Mar;16(2):113-8. doi: 10.1007/s10198-014-0639-8.
4
What is wrong with orphan drug policies? Suggestions for ways forward.孤儿药政策有何问题？前进方向的建议。
Value Health. 2012 Dec;15(8):1182-4. doi: 10.1016/j.jval.2012.08.2202. Epub 2012 Oct 25.
5
Differences in external price referencing in Europe: a descriptive overview.欧洲外部价格参照的差异：描述性概述。
Health Policy. 2012 Jan;104(1):50-60. doi: 10.1016/j.healthpol.2011.09.008. Epub 2011 Oct 19.
6
Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.澳大利亚药品福利计划中所列药品定价安排的透明度。
Aust Health Rev. 2009 May;33(2):192-9. doi: 10.1071/ah090192.